英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
jowel查看　jowel　在百度字典中的解释百度英翻中〔查看〕
jowel查看　jowel　在Google字典中的解释Google英翻中〔查看〕
jowel查看　jowel　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Prospective comprehensive profiling of immune responses to COVID‐19 . . .
    Zanubrutinib is a next‐generation BTK inhibitor, which is more selective and has potentially less off‐target activity, but its impact on the range of immune responses to COVID‐19 vaccination has not been studied in detail As such, this prospective study was conducted to evaluate a comprehensive range of humoral and cellular immune
  • Sustained benefit of zanubrutinib vs ibrutinib in patients with R R CLL . . .
    Although higher rates of any-grade COVID-19 were reported in the zanubrutinib arm, fewer COVID-19–related deaths and fewer treatment discontinuations because of COVID-19 occurred on the zanubrutinib arm compared with ibrutinib As the incidence of COVID-19 infection increased during the trial, the longer duration of drug exposure for
  • Vaccinations in CLL: implications for COVID-19 Free
    Given the various indications for first- (ibrutinib) and second- (acalabrutinib, zanubrutinib) generation BTKi’s in lymphoid malignancies, this could have broader clinical implications Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates [published online ahead of print 147 October 2020]
  • A randomized, placebo-controlled trial of the BTK inhibitor . . .
    Importantly, serological response to coronavirus disease 2019 (COVID-19) was not impacted by zanubrutinib Lower levels of granulocyte colony-stimulating factor, interleukin (IL)-10, monocyte chemoattractant protein-1, IL-4, and IL-13 were observed in zanubrutinib-treated patients Moreover, single-cell transcriptome analysis showed significant
  • Five-Year Follow-Up Confirms Zanubrutinib as a Frontline Option in CLL SLL
    The most common grade 3 or higher treatment-emergent and post-treatment AEs included COVID-19 (zanubrutinib, 9% vs BR, 2%), hypertension (12% vs 6%), and neutropenia (10% vs 41%) There were “low rates of atrial fibrillation flutter [afib flutter], infections, or AEs that limit daily living activities like [gastrointestinal] toxicities
  • Brukinsa and COVID-19 mRNA (Moderna) vaccine Interactions - Drugs. com
    In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of zanubrutinib therapy If you have recently been vaccinated with SARS-CoV-2 (COVID-19) mRNA-LNP vaccine (cvx 312), your doctor may choose to postpone treatment with zanubrutinib for a couple of weeks or more
  • Prospective comprehensive profiling of immune responses to COVID-19 . . .
    Zanubrutinib-treated and treatment-naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID-19 vaccination Overall, 45 patients (median 72 years old) …
  • Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as . . .
    1 Introduction Coronavirus disease (COVID)-19 is the leading global health threat to date caused by a coronavirus (SARS-CoV-2 or nCov-2019) next to severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) [1,2] in this century Though antiviral and antimalarial drugs are being used to control and enhance the recovery rate from COVID-19, the death toll rate is
  • Five-Year Follow-Up Data Show Zanubrutinib Improves Progression-Free . . .
    Zanubrutinib shows significant efficacy in high-risk CLL SLL patients with del(17p), with a 60-month PFS estimate of 72 2% and ORR of 97 3% The SEQUOIA study compares zanubrutinib with bendamustine plus rituximab, highlighting zanubrutinib's superior performance in treatment-naïve patients
  • BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in . . .
    The trial was designed to assess quickly whether treatment with zanubrutinib could help hospitalized patients with COVID-19-related pulmonary distress Non-mechanically ventilated patients were randomized to receive oral zanubrutinib at 320 mg once daily for 28 days plus supportive care, or placebo plus supportive care





中文字典-英文字典  2005-2009